Levin Capital Strategies L.P. Decreases Stock Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Levin Capital Strategies L.P. lowered its stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 42.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,000 shares of the company’s stock after selling 15,000 shares during the quarter. Levin Capital Strategies L.P.’s holdings in Aquestive Therapeutics were worth $71,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in AQST. MONECO Advisors LLC purchased a new stake in shares of Aquestive Therapeutics during the 4th quarter valued at $156,000. New York State Common Retirement Fund increased its position in Aquestive Therapeutics by 713.3% during the 4th quarter. New York State Common Retirement Fund now owns 12,200 shares of the company’s stock valued at $43,000 after buying an additional 10,700 shares in the last quarter. Harvey Capital Management Inc. increased its position in Aquestive Therapeutics by 1,419.3% during the 4th quarter. Harvey Capital Management Inc. now owns 267,390 shares of the company’s stock valued at $952,000 after buying an additional 249,790 shares in the last quarter. Financial Advocates Investment Management raised its stake in Aquestive Therapeutics by 28.2% in the fourth quarter. Financial Advocates Investment Management now owns 50,000 shares of the company’s stock valued at $178,000 after buying an additional 11,000 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in Aquestive Therapeutics in the fourth quarter worth about $69,000. Hedge funds and other institutional investors own 32.45% of the company’s stock.

Analysts Set New Price Targets

AQST has been the topic of a number of recent analyst reports. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Aquestive Therapeutics in a research note on Friday, December 20th. Cantor Fitzgerald assumed coverage on shares of Aquestive Therapeutics in a report on Tuesday, December 17th. They set an “overweight” rating and a $17.00 price objective on the stock. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Aquestive Therapeutics currently has an average rating of “Buy” and an average target price of $11.00.

Aquestive Therapeutics Price Performance

AQST stock opened at $2.80 on Monday. The company has a market capitalization of $255.30 million, a P/E ratio of -6.22 and a beta of 2.67. Aquestive Therapeutics, Inc. has a 12 month low of $2.24 and a 12 month high of $6.23. The firm’s fifty day simple moving average is $3.18 and its 200-day simple moving average is $4.15.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.